1. Opening Hook
Rossari Biotech just reported Q3 FY26 results in a quarter where demand was “soft,” margins were “temporarily impacted,” and patience was officially tested.
Yet management sounded calm—almost Zen—while EBITDA quietly slipped and ROCE flirted with WACC like it’s not a red flag.
Despite EO shortages, labor code shocks, and muted domestic demand, Rossari insists the long-term story is intact. Capacity is ready. Products are approved. Saudi Arabia is calling.
Only one small problem: profits are still stuck in FY23.
But hey, apparently by 2027 everything will align—capacity, margins, ROCE, and maybe even investor sentiment.
Stick around. It gets more interesting when management explains why low margins are actually a “phase,” Saudi capex is totally under control, and bio-surfactants might just save the day.
2. At a Glance
- Revenue up 13% YoY – Not bad, considering demand was allegedly on vacation.
- EBITDA margin at 11.8% – Down from IPO glory days; gravity is undefeated.
- Core B2B EBITDA ~14% – Respectable, until B2C walks in and ruins the party.
- Exports at 33% of revenue – The only thing growing faster than management optimism.
- PAT flat QoQ – Profits have entered monk mode: growth through meditation.
3. Management’s Key Commentary (Decoded)
“We delivered healthy 13% YoY growth despite a softer domestic environment.”
(Translation: Demand was weak, but exports saved us 😏)
“Margins were impacted due to capacity expansion, labor codes, and investments.”
(Translation: Everything costs more now, please wait patiently 😬)
“EO availability is a near-term constraint.”
(
